The presentation confirms strong operational momentum with accelerating revenue growth and margin expansion, but the stock remains a binary event on FDA and CE Mark timelines. Monitor for 510(k) clearance in Q4 2026/Q1 2027 as the key catalyst for US market entry. No new guidance or capital raise was announced.
Price Chart
Executive Summary
SS Innovations filed an 8-K furnishing a June 2026 investor presentation. The presentation highlights strong Q1 2026 revenue growth of 117% YoY to $11.1M, a 48% gross margin (up from 21.2% in Q1 2025), and a cumulative installed base of 210 SSi Mantra systems across 12 countries. The company remains pre-FDA approval in the US (anticipated Q4 2026/Q1 2027) and pre-CE Mark in Europe (anticipated Q4 2026), with 74% insider ownership and a net loss of $3.6M in Q1 2026. This is a routine investor relations update with no new material financial guidance or corporate events.
Key Facts
- Q1 2026 revenue of $11.1M, up 117% YoY from $5.1M in Q1 2025
- Q1 2026 gross margin of 48.0%, up from 21.2% in Q1 2025
- Q1 2026 net loss of $3.6M, improved from $5.7M net loss in Q1 2025
- 210 cumulative SSi Mantra systems installed as of May 31, 2026, up from 194 as of March 31, 2026
- 11,270 cumulative multi-specialty surgeries performed as of May 31, 2026
- Cash of $23.6M (including $7.6M restricted) as of March 31, 2026
- No long-term debt as of March 31, 2026
- US FDA 510(k) submission under review, anticipated clearance Q4 2026/Q1 2027
- EU CE Mark anticipated Q4 2026
- Insider ownership of ~74% as of June 2, 2026
- 200.1M shares outstanding as of June 2, 2026
Financial Impact
Q1 2026 revenue $11.1M (+117% YoY), gross margin 48.0%, net loss $3.6M. Cash $23.6M, no debt.
Risk Factors
- FDA 510(k) clearance delayed beyond Q1 2027
- CE Mark certification delayed beyond Q4 2026
- Cash burn rate of ~$3.6M/quarter may require future capital raise
- High insider ownership (74%) limits float and liquidity
- Revenue concentration in India (87% in 2025) creates geographic risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-068479 |
| Document: ea0294544-8k_ssinnovations.htm | 0001213900-26-068479 |
| Document: 0001213900-26-068479-index-headers.html | 0001213900-26-068479 |
| Document: 0001213900-26-068479-index.html | 0001213900-26-068479 |
| Document: 0001213900-26-068479.txt | 0001213900-26-068479 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $2.37 | awaiting T+5 | — | $2.50 (+5.49%) |
Oct 26, 2026 1d ago | Press Release | $2.37 | awaiting T+5 | — | $2.50 (+5.49%) |
Oct 13, 2026 14d ago | 8-K | $2.55 $2.54 | ▼ −0.39% | ▲ +0.76% | $2.50 (−1.96%) |
Oct 13, 2026 14d ago | 8-K | $2.55 $2.54 | ▲ +0.39% | ▼ −0.76% | $2.50 (+1.96%) |
Oct 9, 2026 18d ago | 424B5 | $2.55 $2.45 | ▲ +3.92% | ▲ +2.43% | $2.50 (+1.96%) |
Oct 5, 2026 22d ago | 8-K | $2.77 $2.55 | ▼ −7.94% | ▼ −8.36% | $2.50 (−9.75%) |
Sep 10, 2026 6w ago | 8-K | $3.30 $3.26 | ▼ −1.21% | ▼ −0.71% | $2.50 (−24.24%) |
Aug 13, 2026 10w ago | 8-K | $3.83 $3.61 | ▼ −5.74% | ▼ −3.78% | $2.50 (−34.73%) |
Jul 17, 2026 14w ago | 8-K | $3.64 $3.57 | ▼ −1.92% | ▼ −1.24% | $2.50 (−31.32%) |
Jul 14, 2026 15w ago | 8-K | $3.67 $3.75 | ▲ +2.18% | ▲ +3.48% | $2.50 (−31.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers